Juan Gonzalez-Valdivieso

Dr. Juan Gonzalez-Valdivieso

University of Valladolid (Spain)
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Juan Gonzalez-ValdiviesoJuan Gonzalez-Valdivieso
Juan Gonzalez-Valdivieso
Alessandra GirottiAlessandra Girotti
Alessandra Girotti
JSJose Schneider
Jose Schneider
FAFrancisco Javier Arias
Francisco Javier Arias

4 March 2023 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
TLTania B. López-Méndez
Tania B. López-Méndez
MSMiguel Sánchez-Álvarez
Miguel Sánchez-Álvarez
FTFlavia Trionfetti
Flavia Trionfetti
JPJosé L. Pedraz
José L. Pedraz
MTMarco Tripodi
Marco Tripodi
Juan Gonzalez-ValdiviesoJuan Gonzalez-Valdivieso
Juan Gonzalez-Valdivieso
In recent years, progress in nanotechnology provided new tools to treat cancer more effectively. Advances in biomaterials tailored for drug delivery have the potential to overcome the limited selectivity and side effects frequently associated with traditional therapeutic agents. While autophagy is pivotal in determining cell fate and adaptation to different challenges, and despite the fact that it is frequently dysregulated in cancer, antitumor therapeutic strategies leveraging on or targeting this process are scarce. This is due to many reasons, including the very contextual effects of autophagy in cancer, low bioavailability and non-targeted delivery of existing autophagy modulatory compounds. Conjugating the versatile characteristics of nanoparticles with autophagy modulators may render these drugs safer and more effective for cancer treatment. Here, we review current standing questions on the biology of autophagy in tumor progression, and precursory studies and the state-of-the-art in harnessing nanomaterials science to enhance the specificity and therapeutic potential of autophagy modulators.

3 January 2020 in Current Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
MSMercedes Santos
Mercedes Santos
SSSofía Serrano-Dúcar
Sofía Serrano-Dúcar
Juan Gonzalez-ValdiviesoJuan Gonzalez-Valdivieso
Juan Gonzalez-Valdivieso
RVReinaldo Vallejo
Reinaldo Vallejo
Alessandra GirottiAlessandra Girotti
Alessandra Girotti
FAF. Javier Arias
F. Javier Arias
: Protein-based polymers are some of the most promising candidates for a new generation of innovative biomaterials as recent advances in genetic-engineering and biotechnological techniques mean that protein-based biomaterials can be designed and constructed with a higher degree of complexity and accuracy. Moreover, their sequences, which are derived from structural protein-based modules, can easily be modified to include bioactive motifs that improve their functions and material-host interactions, thereby satisfying fundamental biological requirements. : The accuracy with which these advanced polypeptides can be produced, and their versatility, self-assembly behavior, stimuli-responsiveness and biocompatibility, means that they have attracted increasing attention for use in biomedical applications such as cell culture, tissue engineering, protein purification, surface engineering and controlled drug delivery. : The biopolymers discussed in this review are elastin-derived protein-based polymers which are biologically inspired and biomimetic materials. This review will also focus on the design, synthesis and characterization of these genetically encoded polymers and their potential utility for controlled drug and gene delivery, as well as in tissue engineering and regenerative medicine.

12 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYanping Yang
Yanping Yang
HYHuan Yang
Huan Yang
YAYago Alcaina
Yago Alcaina
JPJanusz Puc
Janusz Puc
ABAlyssa Birt
Alyssa Birt
MJMoonsoo Jin
Moonsoo Jin
The limited number of targetable tumor-specific antigens and the immunosuppressive nature of the microenvironment within solid malignancies represent major barriers to the success of chimeric antigen receptor (CAR)-T cell therapies. Here, using epithelial cell adhesion molecule (EpCAM) as a model antigen, we used alanine scanning of the complementarity-determining region to fine-tune CAR affinity. This allowed us to identify CARs that could spare primary epithelial cells while still effectively targeting EpCAMhigh tumors. Although affinity-tuned CARs showed suboptimal antitumor activity in vivo, we found that inducible secretion of interleukin-12 (IL-12), under the control of the NFAT promoter, can restore CAR activity to levels close to that of the parental CAR. This strategy was further validated with another affinity-tuned CAR specific for intercellular adhesion molecule-1 (ICAM-1). Only in affinity-tuned CAR-T cells was NFAT activity stringently controlled and restricted to tumors expressing the antigen of interest at high levels. Our study demonstrates the feasibility of specifically gearing CAR-T cells towards recognition of solid tumors by combining inducible IL-12 expression and affinity-tuned CAR.

4 April 2019 in Biomacromolecules
Verified
Journal Article
Closed access
Juan Gonzalez-ValdiviesoJuan Gonzalez-Valdivieso
Juan Gonzalez-Valdivieso
Alessandra GirottiAlessandra Girotti
Alessandra Girotti
RMRaquel Muñoz
Raquel Muñoz
JRJose Carlos Rodriguez-Cabello
Jose Carlos Rodriguez-Cabello
FAF. Javier Arias
F. Javier Arias

1 January 2021 in Journal of Industrial and Engineering Chemistry
Verified
Journal Article
Closed access
RVR. Vallejo
R. Vallejo
Juan Gonzalez-ValdiviesoJuan Gonzalez-Valdivieso
Juan Gonzalez-Valdivieso
MSM. Santos
M. Santos
SRS. Rodriguez-Rojo
S. Rodriguez-Rojo
FAF.J. Arias
F.J. Arias